scispace - formally typeset
A

Atul Gupta

Researcher at University of Cambridge

Publications -  121
Citations -  3560

Atul Gupta is an academic researcher from University of Cambridge. The author has contributed to research in topics: Asthma & Medicine. The author has an hindex of 24, co-authored 109 publications receiving 2461 citations. Previous affiliations of Atul Gupta include Imperial College London & Boston Children's Hospital.

Papers
More filters
Journal ArticleDOI

The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease.

TL;DR: In this article, a consensus exercise was conducted to identify research priorities with the aim of understanding the long-term effects of acute COVID-19, with a focus on people with pre-existing airway disease and the occurrence of new-onset airways disease and associated symptoms.
Journal ArticleDOI

Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach

TL;DR: A multidomain evaluation of systemic steroid responsiveness using pragmatic clinical assessments confirms childhood STRA is heterogeneous and that a complete response in symptoms and inflammatory and physiologic parameters is rare.
Journal ArticleDOI

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype

TL;DR: The long-term safety, pharmacodynamic and efficacy data from this study support a positive benefit-risk profile for mepolizumab in children with severe asthma with an eosinophilic phenotype and were similar to data in studies in adults and adolescents.
Journal ArticleDOI

Genetic testing in children with surfactant dysfunction

TL;DR: The UK experience in genetic diagnoses of surfactant protein dysfunction disorders is presented and a referral algorithm for neonates and children with persistent respiratory problems is developed to develop a validated algorithm for genetic evaluation with a need for international networking.
Journal ArticleDOI

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.

TL;DR: The pharmacokinetics and pharmacodynamics of mepolizumab following subcutaneous (SC) administration in children 6 to 11 years of‐age with severe eosinophilic asthma are characterized.